Tara is a strategic patent litigator and regulatory counselor with deep experience guiding life sciences, pharmaceutical, agrochemical, technology, and other innovation driven companies through the legal, operational, and regulatory complexities that arise across the full product development lifecycle. Her practice spans complex patent litigation, portfolio strategy, regulatory counseling, opinion work, and diligence, with particular strength at the intersection of patent law, agency frameworks, and commercial strategy.
Tara advises both clinical stage and commercial stage companies on how to build, protect, and position their assets while navigating evolving regulatory and compliance requirements. In the life sciences and pharmaceutical sectors, her work includes matters under the Hatch Waxman Amendments, the Biologics Price Competition and Innovation Act (BPCIA), controlled substance handling, REMS related considerations, data integrity and documentation practices, and aligning IP strategy with development phase and exclusivity goals. Outside the pharmaceutical arena, Tara regularly counsels and represents clients in protecting, defending, and commercializing innovations in fields such as agrochemicals, crop protection technologies, lighting and LED systems, software and digital platforms, and chemical and materials engineering.
As a litigator, Tara brings rigorous patent analysis, regulatory fluency, and practical business judgment to each engagement. Tara has led teams through all stages of litigation—from pre suit investigations and strategic case development to trial, appeal, and post grant proceedings before federal district courts, the Federal Circuit, and the U.S. Patent and Trademark Office. Her experience includes managing complex fact and expert discovery, taking and defending key depositions, drafting and arguing dispositive motions, and examining witnesses at trial.
Clients rely on Tara not only for her command of patent and regulatory law but also for her ability to operate as a cross functional strategic partner. She works closely with clinical, regulatory, CMC, quality, engineering, product, and executive teams to anticipate litigation and regulatory risks, ensure alignment between scientific or technical development and external communications, and build IP and documentation frameworks that withstand scrutiny from competitors, investors, and regulators. She advises on patent portfolio development, freedom to operate assessments, licensing strategy, regulatory exclusivity positioning, and the IP components of transactions and development stage collaborations.
Whether supporting an emerging company preparing for pivotal studies, assisting a pharmaceutical or agrochemical manufacturer bring a product to market, helping a technology company protect or defend against a hardware or software platform, or guiding any manufacturer through a competitive IP landscape, Tara brings clear judgment, disciplined execution, and a balanced understanding of scientific, technical, legal, and commercial priorities. Her integrated litigation, IP, and regulatory perspective enables companies across industries to advance innovation with confidence while protecting long term asset value.
*Matter completed prior to joining Benesch.
Representative Experience
- Key member of trial team for a pharmaceutical company in ANDA litigation and on appeal with respect to numerous patents concerning an HIV antiviral.*
-
Key member of trial team that secured an invalidity ruling after appeal with respect to a patent in ANDA litigation concerning an ACE inhibitor.*
-
Key member of trial team that secured an invalidity ruling with respect to a patent in ANDA litigation concerning a steroid used to treat asthma.*
- Key member of team that secured victory on behalf of pharmaceutical company at the District Court and Federal Circuit levels, not only defeating a preliminary injunction motion but invalidating two patents upon summary judgment relating to a drug used to treat or prevent osteoporosis.*
- Member of team that secured a non-infringement ruling on summary judgment and on appeal with respect to a patent in ANDA litigation concerning a cephalasporin antibiotic.*
- Represented a pharmaceutical company in ANDA litigation involving numerous patents directed to a drug used to treat iron deficiency anemia in patients with chronic kidney disease (CKD).*
-
Represented pharmaceutical companies in ANDA litigation involving three polymorph patents relating to a coronary vasodilator used in pharmacologic stress testing.*
-
Represented pharmaceutical company in ANDA litigation involving formulation and device patents relating to a bronchodilator.*

